Novartis Ag Adr Stock Return On Equity

NVS Stock  USD 96.73  0.85  0.89%   
Novartis AG ADR fundamentals help investors to digest information that contributes to Novartis' financial success or failures. It also enables traders to predict the movement of Novartis Stock. The fundamental analysis module provides a way to measure Novartis' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Novartis stock.
Return On Equity is likely to gain to 0.33 in 2024.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Novartis Return On Equity Analysis

Novartis' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Novartis Return On Equity

0.33

Return On Equity

 = 

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current Novartis Return On Equity

    
  0.16  
Most of Novartis' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novartis AG ADR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Novartis Return On Equity Driver Correlations

Understanding the fundamental principles of building solid financial models for Novartis is extremely important. It helps to project a fair market value of Novartis Stock properly, considering its historical fundamentals such as Return On Equity. Since Novartis' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Novartis' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Novartis' interrelated accounts and indicators.
0.660.920.520.710.920.920.7-0.01-0.050.00.880.410.55-0.070.930.750.610.760.98-0.010.830.10.370.26-0.360.190.290.260.040.22
0.660.360.040.70.390.740.260.390.16-0.660.860.750.61-0.440.720.360.240.810.640.510.35-0.490.27-0.35-0.420.60.3-0.290.11-0.1
0.920.360.650.430.990.830.71-0.08-0.060.310.620.260.280.120.770.620.520.470.92-0.260.880.420.250.38-0.27-0.140.170.450.180.29
0.520.040.650.120.690.350.23-0.26-0.210.330.260.04-0.070.10.330.550.410.280.47-0.290.440.460.210.5-0.72-0.160.030.310.10.2
0.710.70.430.120.490.610.450.14-0.14-0.40.880.230.62-0.250.850.730.460.910.680.320.35-0.430.360.15-0.290.580.24-0.05-0.180.09
0.920.390.990.690.490.820.7-0.05-0.120.240.650.270.270.060.80.680.560.540.92-0.180.840.380.310.38-0.36-0.070.20.40.20.27
0.920.740.830.350.610.820.65-0.010.14-0.10.840.430.49-0.120.870.580.360.660.94-0.010.87-0.010.180.09-0.280.140.150.070.020.15
0.70.260.710.230.450.70.65-0.28-0.50.290.530.040.29-0.030.690.460.370.440.77-0.280.80.230.270.210.060.030.110.18-0.030.1
-0.010.39-0.08-0.260.14-0.05-0.01-0.280.22-0.50.080.67-0.06-0.120.08-0.29-0.160.17-0.030.51-0.35-0.160.05-0.53-0.010.20.240.010.76-0.01
-0.050.16-0.06-0.21-0.14-0.120.14-0.50.22-0.21-0.020.190.090.09-0.11-0.2-0.2-0.22-0.080.12-0.03-0.16-0.25-0.170.13-0.18-0.03-0.01-0.010.05
0.0-0.660.310.33-0.40.24-0.10.29-0.5-0.21-0.36-0.54-0.290.74-0.16-0.020.07-0.480.05-0.830.30.85-0.150.650.39-0.77-0.330.75-0.130.54
0.880.860.620.260.880.650.840.530.08-0.02-0.360.490.75-0.270.920.740.590.930.850.280.59-0.290.430.08-0.390.530.37-0.02-0.120.1
0.410.750.260.040.230.270.430.040.670.19-0.540.490.36-0.380.36-0.020.230.480.360.530.11-0.150.35-0.57-0.340.420.51-0.120.58-0.16
0.550.610.28-0.070.620.270.490.29-0.060.09-0.290.750.36-0.250.620.530.630.620.490.360.29-0.350.59-0.04-0.060.520.510.0-0.360.01
-0.07-0.440.120.1-0.250.06-0.12-0.03-0.120.090.74-0.27-0.38-0.25-0.19-0.11-0.03-0.39-0.05-0.750.030.72-0.360.670.48-0.77-0.370.84-0.110.9
0.930.720.770.330.850.80.870.690.08-0.11-0.160.920.360.62-0.190.760.520.830.930.150.69-0.120.420.13-0.310.330.30.110.020.13
0.750.360.620.550.730.680.580.46-0.29-0.2-0.020.74-0.020.53-0.110.760.760.740.680.090.52-0.040.50.52-0.470.320.320.15-0.290.18
0.610.240.520.410.460.560.360.37-0.16-0.20.070.590.230.63-0.030.520.760.580.50.120.350.20.790.41-0.260.330.70.35-0.10.22
0.760.810.470.280.910.540.660.440.17-0.22-0.480.930.480.62-0.390.830.740.580.710.420.38-0.360.510.04-0.530.710.41-0.13-0.040.0
0.980.640.920.470.680.920.940.77-0.03-0.080.050.850.360.49-0.050.930.680.50.71-0.060.870.120.30.22-0.290.110.180.240.040.22
-0.010.51-0.26-0.290.32-0.18-0.01-0.280.510.12-0.830.280.530.36-0.750.150.090.120.42-0.06-0.32-0.710.4-0.63-0.310.760.39-0.580.2-0.56
0.830.350.880.440.350.840.870.8-0.35-0.030.30.590.110.290.030.690.520.350.380.87-0.320.270.070.31-0.12-0.11-0.010.22-0.090.14
0.1-0.490.420.46-0.430.38-0.010.23-0.16-0.160.85-0.29-0.15-0.350.72-0.12-0.040.2-0.360.12-0.710.270.00.520.2-0.74-0.050.80.280.6
0.370.270.250.210.360.310.180.270.05-0.25-0.150.430.350.59-0.360.420.50.790.510.30.40.070.0-0.06-0.270.50.810.040.1-0.12
0.26-0.350.380.50.150.380.090.21-0.53-0.170.650.08-0.57-0.040.670.130.520.410.040.22-0.630.310.52-0.060.02-0.38-0.210.66-0.440.69
-0.36-0.42-0.27-0.72-0.29-0.36-0.280.06-0.010.130.39-0.39-0.34-0.060.48-0.31-0.47-0.26-0.53-0.29-0.31-0.120.2-0.270.02-0.4-0.190.33-0.120.29
0.190.6-0.14-0.160.58-0.070.140.030.2-0.18-0.770.530.420.52-0.770.330.320.330.710.110.76-0.11-0.740.5-0.38-0.40.5-0.57-0.08-0.53
0.290.30.170.030.240.20.150.110.24-0.03-0.330.370.510.51-0.370.30.320.70.410.180.39-0.01-0.050.81-0.21-0.190.5-0.030.3-0.19
0.26-0.290.450.31-0.050.40.070.180.01-0.010.75-0.02-0.120.00.840.110.150.35-0.130.24-0.580.220.80.040.660.33-0.57-0.030.10.82
0.040.110.180.1-0.180.20.02-0.030.76-0.01-0.13-0.120.58-0.36-0.110.02-0.29-0.1-0.040.040.2-0.090.280.1-0.44-0.12-0.080.30.1-0.11
0.22-0.10.290.20.090.270.150.1-0.010.050.540.1-0.160.010.90.130.180.220.00.22-0.560.140.6-0.120.690.29-0.53-0.190.82-0.11
Click cells to compare fundamentals

Novartis Return On Equity Historical Pattern

Today, most investors in Novartis Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Novartis' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's return on equity growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Novartis return on equity as a starting point in their analysis.
   Novartis Return On Equity   
       Timeline  
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition

Novartis Total Stockholder Equity

Total Stockholder Equity

57.16 Billion

At this time, Novartis' Total Stockholder Equity is comparatively stable compared to the past year.
Based on the latest financial disclosure, Novartis AG ADR has a Return On Equity of 0.1615. This is 100.67% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The return on equity for all United States stocks is 152.1% lower than that of the firm.

Novartis Return On Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novartis' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Novartis could also be used in its relative valuation, which is a method of valuing Novartis by comparing valuation metrics of similar companies.
Novartis is currently under evaluation in return on equity category among related companies.

Novartis Fundamentals

About Novartis Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Novartis AG ADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novartis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novartis AG ADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2024
Return On Equity 0.32  0.33 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Novartis AG ADR is a strong investment it is important to analyze Novartis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Novartis' future performance. For an informed investment choice regarding Novartis Stock, refer to the following important reports:
Check out Novartis Piotroski F Score and Novartis Altman Z Score analysis.
You can also try the Stocks Directory module to find actively traded stocks across global markets.

Complementary Tools for Novartis Stock analysis

When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Money Managers
Screen money managers from public funds and ETFs managed around the world
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Is Novartis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novartis. If investors know Novartis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novartis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
4.987
Dividend Share
3.919
Earnings Share
4.1
Revenue Per Share
22.467
Quarterly Revenue Growth
0.074
The market value of Novartis AG ADR is measured differently than its book value, which is the value of Novartis that is recorded on the company's balance sheet. Investors also form their own opinion of Novartis' value that differs from its market value or its book value, called intrinsic value, which is Novartis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novartis' market value can be influenced by many factors that don't directly affect Novartis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novartis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Novartis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novartis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.